Ge Long Hui A P P·2026-01-26 12:02Core Viewpoint - *ST Shuangcheng (002693.SZ) is expected to turn a profit in 2025, with net profit attributable to shareholders projected between 16 million to 23 million yuan, marking a significant turnaround from losses in the previous year [1] Financial Performance - The company anticipates a total profit growth of 107.53% to 111.30% year-on-year, with net profit attributable to shareholders expected to increase by 120.43% to 129.37% [1] - Revenue is projected to be between 250 million to 290 million yuan [1] Factors Influencing Profit Changes - The company is focusing on international development to counteract domestic drug price declines, leading to steady growth in export sales and advancements in overseas R&D projects [1] - The approval of the U.S. registration application for injectable paclitaxel (albumin-bound) is expected to drive significant revenue growth following its rapid sales post-approval [1] - The absence of fair value loss from Zhongrong Trust financial products, which impacted the previous year's results, and a reduction in asset impairment losses have also contributed to the turnaround [1]